Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar® in Advanced Renal Cell Carcinoma
Phase 4
N/A
N/A
N/A
N/A
Not Enrolling
Both
Carcinoma, Renal Cell
Both
Carcinoma, Renal Cell
Trial Information
Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar® in Advanced Renal Cell Carcinoma
Inclusion Criteria:
- Patients with diagnosis of advanced Renal Cell Carcinoma (RCC) and decision taken by
the investigator to prescribe Sorafenib
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Efficacy related variables are status of tumor / metastases.
Outcome Time Frame:
After 12 months, or at discontinuation of therapy or at end of study (whatever is earlier)
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
India: Drugs Controller General of India
Study ID:
15246
NCT ID:
NCT01353794
Start Date:
March 2013
Completion Date:
January 2016
Related Keywords:
- Carcinoma, Renal Cell
- SORAFENIB
- RENAL CELL CARCINOMA
- TYROSINE KINASE INHIBITOR
- OBSERVATIONAL STUDY
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
